Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization

Cell Reports(2022)10.1016/j.celrep.2021.110216Source: DataRank Database

ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization is a research paper published in Cell Reports (2022). On theSindex it has a DataRank of 0. It has been cited 76 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access76 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (13 grants)OA: goldTopics (21)IDs (PubMed)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (27)

Brendan Mullan,Ramya Ravindran ORCID,Dana Messinger ORCID,Ruby Siada ORCID,Jessica Cummings

Live enrichment

PubMed:35021084

U.S. Department of Defense

Grant: CA201129P1

NCI

Grant: P30 CA046592-29

NINDS

Grant: R37NS094804

NINDS

Grant: R21NS107894

NINDS

Grant: K08-NS099427-01

NINDS

Grant: R01-NS119231

National Institutes of Health

Grant: 5R01NS119231-04

The role of ATRX mutation in the epigenetic dysregulation of cell cycle in pediatric high-grade glioma

National Institutes of Health

Grant: 5K08NS099427-03

Targeting ATRX-Deficient Pediatric GBM

National Institutes of Health

Grant: 5R37NS094804-06

Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic Strategies

National Institutes of Health

Grant: 3R01NS105556-03S1

Interactions between the tumor cells and the neuro-immune microenvironment in mutant IDH1 gliomas: implications for therapeutics

National Institutes of Health

Grant: 3P30CA046592-31S7

Cancer Center Support Grant 2018-2023

National Institutes of Health

Grant: 1R21NS107894-01A1

Immune-mediated therapies in a genetically engineered murine model of diffuse intrinsic pontine glioma

National Institutes of Health

Grant: 5R01NS110572-05

Unraveling metabolic dependencies in H3K27M mutant Diffuse Intrinsic Pontine Gliomas

goldLicense: cc-by-nc-nd

publisherhttp://www.cell.com/article/S2211124721017204/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2211124721017204?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211124721017204?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8759735

https://doi.org/10.1016/j.celrep.2021.110216

Fields of Study

0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

MaleX-linked Nuclear ProteinBrain NeoplasmsCell CyclePrimary Cell CultureCell Cycle CheckpointsGliomaIsocitrate DehydrogenaseHistonesMice, Inbred C57BLMiceCell Line, TumorCheckpoint Kinase 1MutationAnimalsHumansFemaleNeoplasm Recurrence, Local